Biodesix said this week that data from an analysis of serum and plasma samples from a Phase II non-small cell lung cancer study demonstrate that its Veristrat test is able to identify patients likely to benefit when treated with erlotinib – marketed by Roche as Tarceva – and erlotinib combined with gemcitabine.
The results were presented this week at the Chicago Multidisciplinary Symposia in Thoracic Oncology by Thomas Stinchcombe, associate professor of hematology/oncology at the University of North Carolina Lineberger Comprehensive Cancer Center.
In the study, which looked at 105 elderly advanced NSCLC patients, those identified as Veristrat "good" had statistically significant improvements in progression-free survival and overall survival compared to those classified as Veristrat "poor" when treated with erlotinib. Veristrat "good" patients also showed better PFS and OS compared to "poor" patients when treated with erlotinib combined with gemcitabine.
The study showed no significant difference between Veristrat "good" and "poor" patients treated with gemcitabine alone.